← Leaderboards
Susmita Sahoo
Northwestern University At Chicago
$7,920,822
Attributed
$8,844,326
Total exposure
5
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.7M · FY2014–24$2M$1.5M$1M$500K$0
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$8,844,326 · 5
By mechanism
R01$8,824,326 · 4
R13$20,000 · 1
Top collaborators
- Rupangi C Vasavada4 shared
Most similar at Northwestern University At Chicago
Same institution · by research overlap
- David Y Barefield$2,338,574
- Anthony Martin Gacita$191,756
- Daniel Arango$1,187,000
- Yadav Sapkota$3,246,319
- Tanner O Monroe$217,870
Others in their field
Top investigators on “Molecular”
- David Heimbrook · Leidos Biomedical Research, Inc.$871,088,761
- Leonard Freedman · Leidos Biomedical Research, Inc.$468,573,385
- Richard Webby · St. Jude Children'S Research Hospital$254,843,170
- Larry Arthur$238,531,074
- Gregory H Reaman · National Childhood Cancer Foundation$230,630,913
- Ralph Parchment · Leidos Biomedical Research, Inc.$193,231,914
Research focus
MolecularMediatingUptakeResistanceInnovationMicrornasInsightMyocardialCell PhysiologyCardiac MyocytesCardiacIn VivoEventBaseCardiovascular SystemTraffickingIn VitroPlayCell TypeCardiovascular DiseasesMyocardiumCellsHeart FailureNanovesicle
Grant awards (18)
Circulating Extracellular Vesicles in the Pathogenesis of Type 1 Diabetes$443,154
R01 · FY2024 · DK
Circulating Extracellular Vesicles in the Pathogenesis of Type 1 Diabetes$461,618
R01 · FY2023 · DK
AAV-Exosomes: Escaping Neutralizing Antibody and Enhancing Delivery$796,394
R01 · FY2022 · HL · contact PI
Circulating Extracellular Vesicles in the Pathogenesis of Type 1 Diabetes$461,618
R01 · FY2022 · DK
AAV-Exosomes: Escaping Neutralizing Antibody and Enhancing Delivery$798,024
R01 · FY2021 · HL · contact PI
Circulating Extracellular Vesicles in the Pathogenesis of Type 1 Diabetes$480,618
R01 · FY2021 · DK
Dysregulated Adenosine Methylation of mRNA as a Novel Mechanism of Heart Failure$423,750
R01 · FY2021 · HL · contact PI
AAV-Exosomes: Escaping Neutralizing Antibody and Enhancing Delivery$799,583
R01 · FY2020 · HL · contact PI
Dysregulated Adenosine Methylation of mRNA as a Novel Mechanism of Heart Failure$423,750
R01 · FY2020 · HL · contact PI
AAV-Exosomes: Escaping Neutralizing Antibody and Enhancing Delivery$816,898
R01 · FY2019 · HL · contact PI
Dysregulated Adenosine Methylation of mRNA as a Novel Mechanism of Heart Failure$423,750
R01 · FY2019 · HL · contact PI
Therapeutic Mechanisms of Human CD34 Exosomes$423,750
R01 · FY2018 · HL · contact PI
Dysregulated Adenosine Methylation of mRNA as a Novel Mechanism of Heart Failure$423,750
R01 · FY2018 · HL · contact PI
Therapeutic Mechanisms of Human CD34 Exosomes$423,750
R01 · FY2017 · HL · contact PI
Diversity of Extracellular Vesicle (EV) Composition and Functionin Disease Diagnosis and Therapeutics$20,000
R13 · FY2017 · TR · contact PI
Therapeutic Mechanisms of Human CD34 Exosomes$423,750
R01 · FY2016 · HL · contact PI
Therapeutic Mechanisms of Human CD34 Exosomes$413,919
R01 · FY2014 · HL · contact PI
Therapeutic Mechanisms of Human CD34 Exosomes$386,250
R01 · FY2014 · HL · contact PI